CoChat

Global Trends in the Epidemiology and Management of Dyslipidemia

Liu, Tianxiao, Zhao, Dong, Qi, Yue · 2022 · Journal of Clinical Medicine
Cited by 62

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Dyslipidemia, especially a circulating non-optimal level of cholesterol, is one of the most important risk factors for atherosclerotic cardiovascular disease (ASCVD), which accounts for the most deaths worldwide. Maintaining a healthy level of blood cholesterol is an important prevention strategy for ASCVD, through lifestyle intervention or cholesterol-lowering therapy. Over the past three decades, the epidemiology and management of dyslipidemia has changed greatly in many countries. Therefore, it is necessary to understand the current epidemiologic features of dyslipidemia and challenges from a global perspective.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jcm11216377

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 31

  1. Chen, 2021, Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis, Nat. Rev. Cardiol., 19, 228, 10.1038/s41569-021-00629-x · DOI · Paper page
  2. Almahmeed, 2016, Dyslipidaemia in the Middle East: Current status and a call for action, Atherosclerosis, 252, 182, 10.1016/j.atherosclerosis.2016.07.925 · DOI
  3. NCD Risk Factor Collaboration (2020). Repositioning of the global epicentre of non-optimal cholesterol. Nature, 582, 73–77. · DOI · Paper page
  4. Hoffmann, 2018, A large electronic-health-record-based genome-wide study of serum lipids, Nat. Genet., 50, 401, 10.1038/s41588-018-0064-5 · DOI · Paper page
  5. Mortensen, M.B., Falk, E., and Schmidt, M. (2017). Twenty-Year Nationwide Trends in Statin Utilization and Expenditure in Denmark. Circ. Cardiovasc. Qual. Outcomes, 10. · DOI · Paper page
  6. Vancheri, 2016, Time trends in statin utilisation and coronary mortality in Western European countries, BMJ Open, 6, e010500, 10.1136/bmjopen-2015-010500 · DOI · Paper page
  7. Zhu, 2018, 2016 Chinese guidelines for the management of dyslipidemia in adults, J. Geriatr. Cardiol., 15, 1
  8. Oliva, 2021, Executive Summary of the 2020 Clinical Practice Guidelines for the Management of Dyslipidemia in the Philippines, J. ASEAN Fed. Endocr. Soc., 36, 5, 10.15605/jafes.036.01.01 · DOI
  9. Malaysia Ministry of Health (2022, July 01). Management of Dyslipidaemia 2017 5th Edition. Available online: http://www.acadmed.org.my/index.cfm?&menuid=67.
  10. Iyengar, 2016, Lipid Association of India Expert Consensus Statement on Management of Dyslipidemia in Indians 2016: Part 1, J. Assoc. Physicians India, 64, 7
  11. Rhee, 2019, 2018 Guidelines for the Management of Dyslipidemia in Korea, J. Lipid Atheroscler., 8, 78, 10.12997/jla.2019.8.2.78 · DOI · Paper page
  12. Banach, 2021, PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021, Arch. Med. Sci., 17, 1447, 10.5114/aoms/141941 · DOI
  13. Jellinger, 2017, American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease-Executive Summarycomplete Appendix to Guidelines, Endocr. Pract., 23, 479, 10.4158/EP171764.GL · DOI · Paper page
  14. Klug, 2018, South African dyslipidaemia guideline consensus statement: 2018 update A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA), S. Afr. Med. J., 108, 973, 10.7196/SAMJ.2018.v108i11.13383 · DOI
  15. Yokoyama, 2007, Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis, Lancet, 369, 1090, 10.1016/S0140-6736(07)60527-3 · DOI · Paper page
  16. Hai, Q., and Smith, J.D. (2021). Acyl-Coenzyme A: Cholesterol Acyltransferase (ACAT) in Cholesterol Metabolism: From Its Discovery to Clinical Trials and the Genomics Era. Metabolites, 11. · DOI
  17. Zhao, 2015, Cardiovascular risk assessment: A global perspective, Nat. Rev. Cardiol., 12, 301, 10.1038/nrcardio.2015.28 · DOI
  18. Yebyo, H.G., Zappacosta, S., Aschmann, H.E., Haile, S.R., and Puhan, M.A. (2020). Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: A benefit-harm balance modelling study. BMC Cardiovasc. Disord., 20. · DOI
  19. Lu, Y., Wang, P., Zhou, T., Lu, J., Spatz, E.S., Nasir, K., Jiang, L., and Krumholz, H.M. (2018). Comparison of Prevalence, Awareness, Treatment, and Control of Cardiovascular Risk Factors in China and the United States. J. Am. Heart Assoc., 7. · DOI · Paper page
  20. Kim, 2022, Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): A randomised, open-label, non-inferiority trial, Lancet, 400, 380, 10.1016/S0140-6736(22)00916-3 · DOI · Paper page
  21. Salami, 2018, National Trends in Nonstatin Use and Expenditures among the US Adult Population From 2002 to 2013: Insights from Medical Expenditure Panel Survey, J. Am. Heart Assoc., 7, e007132, 10.1161/JAHA.117.007132 · DOI · Paper page
  22. Zhang, 2018, Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: A nationally representative survey of 163,641 adults, Int. J. Cardiol., 260, 196, 10.1016/j.ijcard.2017.12.069 · DOI · Paper page
  23. Li, 2015, ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): A retrospective analysis of hospital data, Lancet, 385, 441, 10.1016/S0140-6736(14)60921-1 · DOI · Paper page
  24. Xing, 2019, Prehospital statin use and low-density lipoprotein cholesterol levels at admission in acute coronary syndrome patients with history of myocardial infarction or revascularization: Findings from the Improving Care for Cardiovascular Disease in China (CCC) project, Am. Heart J., 212, 120, 10.1016/j.ahj.2019.02.019 · DOI
  25. Lu, 2021, Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China, JAMA Netw. Open, 4, e2127573, 10.1001/jamanetworkopen.2021.27573 · DOI · Paper page
  26. Lazar, 2011, Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era, Circulation, 124, 146, 10.1161/CIRCULATIONAHA.110.986349 · DOI · Paper page
  27. Heller, 2017, Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke, Circulation, 136, 1087, 10.1161/CIRCULATIONAHA.117.027067 · DOI · Paper page
  28. Wang, 2020, Impact of China’s Low Centralized Medicine Procurement Prices on the Cost-Effectiveness of Statins for the Primary Prevention of Atherosclerotic Cardiovascular Disease, Glob. Heart, 15, 43, 10.5334/gh.830 · DOI
  29. Yang, 2020, Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis, Drug Des. Dev. Ther., 14, 157, 10.2147/DDDT.S213968 · DOI
  30. Pan, 2016, The prevalence, awareness, treatment and control of dyslipidemia among adults in China, Atherosclerosis, 248, 2, 10.1016/j.atherosclerosis.2016.02.006 · DOI · Paper page
  31. Writing Committee, Lloyd-Jones, D.M., Morris, P.B., Ballantyne, C.M., Birtcher, K.K., Covington, A.M., DePalma, S.M., Minissian, M.B., Orringer, C.E., and Smith, S.C. (2022). 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J. Am. Coll. Cardiol., 80, 1366–1418. · DOI · Paper page

Cited by

See all 62

Metadata

Authors
Liu, T., Zhao, D., & Qi, Y.
Venue
Journal of Clinical Medicine
Publisher
MDPI AG
Published
2022-10-28
Volume
11
Issue
21
Pages
6377
ISSN
2077-0383
Cited by
62
References
20
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.